Press Releases | News | Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.
Tempus Publishes Study Highlighting Benefits of Concurrent RNA …
4 days ago · CHICAGO--(BUSINESS WIRE)--Nov. 11, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.
Tempus Molecular Profiling Integration Now Available Through …
3 days ago · CHICAGO--(BUSINESS WIRE)--Nov. 12, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into ...
Tempus Molecular Profiling Integration Now Available Through …
2 days ago · CHICAGO, November 12, 2024--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with ...
Tempus AI to buy genetic testing company for $600M
Nov 6, 2024 · Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions, said the purchase will provide expanded testing capabilities for inherited cancer risk. Ambry, based in Aliso Viejo, California, is a leader in hereditary ...
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust …
Nov 5, 2024 · Tempus AI Inc reported a 33% revenue growth, reaching $180.9 million for Q3 2024. The company's data and services revenue accelerated to 64.4% year-over-year growth, with the data licensing ...
Tempus AI Reports Growth and Strategic Acquisition
Nov 5, 2024 · The company reported a 33% year-over-year revenue growth reaching $180.9 million, with accelerated growth in its data and services segment at 64.4%. Despite a net loss of $75.8 million, Tempus ...
Google-backed Tempus AI closes first day of trading up 9% in …
Jun 14, 2024 · Tempus AI, a health-care diagnostics company that uses AI to interpret medical tests to help physicians provide more accurate treatment for their patients, rose by as much as 15% in its...
News Releases - Tempus AI
Sep 12, 2024 · CHICAGO -- (BUSINESS WIRE)--Nov. 4, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024 . The company also announced that it has entered.
Tempus rises 9% on the first day of trading, demonstrating …
Jun 14, 2024 · Tempus rises 9% on the first day of trading, demonstrating investor appetite for a health tech with a promise of AI. Tempus, a genomic testing and data analysis company started by Eric...